Pablo Rubinstein, MD

Pablo Rubinstein, MD, is Vice President of the New York Blood Center (NYBC) and Chief Innovation Officer of NYBC's National Cord Blood Program (NCBP).

Dr. Rubinstein graduated in Chile as a physician and surgeon. He received advanced training in hematology and immunology at Mt. Sinai Hospital in New York, in histocompatibility genetics at the Jackson Laboratory in Bar Harbor, Maine, and in human transplantation antigens at both Columbia University in New York and at the University of Leiden in The Netherlands. He has held the positions of Professor of Genetics at the University of Chile before, and of Pathology at Columbia University, concurrently until 2008, with his tenure at the New York Blood Center.

In 1989, Dr. Rubinstein originated the concept of public cord blood banking, obtained the sponsorship of the National Heart, Lung and Blood Institute of the National institutes of Health and (in 1992) founded the first public cord blood bank in the world, at New York Blood Center. This program received the first FDA IND for cord blood banking in 1996. Together with colleagues from Europe and Japan, Dr. Rubinstein was a founder of Netcord in 1997. With his colleagues at NCBP, he reported on cord blood banking methodology and on the clinical outcomes of the largest series of patients receiving cord blood stem cell transplants from a single cord blood bank. In 2011, under his leadership, NCBP became the first cord blood bank to receive licensure by the U.S.Food and Drug Administration for their hematopoietic progenitor cells-cord (HPC, Cord Blood) cell therapy product, HEMACORD®. Since its inception, the NCBP has provided more than 5,300 cord blood units to Transplant Centers worldwide.

In addition to other scientific awards, Dr. Rubinstein received the Shirley Nolan Award of the World Marrow Donor Association, in 2012, and the Prix Galien USA, for HEMACORD®, named Best Biotechnology Product of 2014.

Dr. Rubinstein is the author of 250 peer-reviewed research papers.